Brief: Biotalys FY Loss For The Period Widens To EUR 16.9 Mln

Biotalys NV

11/03/2022 06:35

March 11 (Reuters) - Biotalys NV  BTLS.BR :
    * YEAR-END CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 56.1
MILLION
    * FY LOSS FOR PERIOD EUR 16.9 MILLION VERSUS LOSS EUR 10.8
MILLION
YEAR AGO
    * WE WILL MERGE CURRENT BIOFUN-5 AND BIOFUN-6 PROGRAMS TO
CONSOLIDATE EFFORTS IN BIOFUNGICIDE SPACE AND FOCUS ON PROVIDING
GROWERS A COMPLEMENTARY AND DIFFERENTIATED BIOCONTROL SOLUTION
BY 2028
    * FY OPERATING LOSS EUR 18.1 MILLION VERSUS LOSS EUR 13.3
MILLION
YEAR AGO
    * FY RESEARCH AND DEVELOPMENT EXPENSES EUR 13.9 MILLION
VERSUS EUR
11.5 MILLION YEAR AGO
    * BASIC AND DILUTED LOSS PER SHARE FOR 2021 AMOUNTED TO EUR
1.10
COMPARED TO EUR 14.33 IN 2020
    * COMPANY EXPECTS CASH BURN IN 2022 TO RANGE BETWEEN EUR 27
AND 29
MILLION
    * OUR FIRST PROTEIN-BASED BIOCONTROL EVOCA IS EXPECTED TO
RECEIVE
EPA REGULATORY APPROVAL IN H2 2022
    * EVOCA IS ON TRACK FOR MARKET CALIBRATION IN SELECTED
STATES IN
U.S
    * SEES FOR 2022 INITIATING THE MARKET CALIBRATION IN THE US
WITH
OUR PARTNER BIOBEST

Source text for Eikon:  ID:nGNE4g5lqs 
Further company coverage:  BTLS.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))